SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending as a multichain meme coin, highlighted by its presence across Solana, BSC, CRO, and Ethereum (BASE) via Layerzero technology and an active deflationary burn mechanism. The engaged community touts its organic growth and partnerships, encouraging wider adoption of the asset.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as escalating global geopolitical tensions amplify the urgent demand for secure Western heavy rare earth supplies essential for defense and technology. The community is actively debating the strategic significance and potential undervaluation of CRML's Tanbreez project, while awaiting its Bankable Feasibility Study update and noting dynamic short interest.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending as it approaches its Q4 earnings report, with community discussion centered on its strategic shift into Physical AI and Humanoid Robotics, coupled with aggressive recruitment and potential defense contracts. Investors are closely monitoring for growth acceleration, robust financial performance, and any emerging M&A speculation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the confirmed departure of a prominent FDA official, widely perceived as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, alongside high anticipation for a late-breaking Phase 3 data presentation at a major medical conference, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly (DPRO) is garnering significant attention following new U.S. Air Force contracts, successful border security demonstrations, and a recent $50 million capital raise aimed at scaling production capabilities. The community is weighing these catalysts against recent volatility, anticipating DPRO's role in the expanding drone defense sector driven by geopolitical needs and the push for domestic manufacturing.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending following a strong earnings report and significantly raised long-term revenue guidance, driven by robust demand for its AI and data center solutions, which has led to multiple analyst upgrades. While many celebrate its undervalued position as an AI infrastructure play, community discussions also highlight skepticism about its ability to hold gains after not being included in the S&P 500.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

GUSH is trending amidst escalating Middle East tensions, particularly concerning potential Strait of Hormuz disruptions and regional conflict, which is fueling a "war trade" narrative among many. However, a frustrated segment of the community is actively debating the leveraged ETF's underperformance relative to broader crude oil price movements.

Almonty Industries, Inc. engages in mining, processing and shipment of tungsten concentrates. Its projects include Los Santos, Valtreixal, Almonty Korea Tungsten, Almonty Korea Moly, and Panasquiera. The company was founded on September 28, 2009 and is headquartered in Toronto, Canada.

Almonty Industries Inc

Almonty Industries is gaining significant attention due to multiple analyst upgrades and a parabolic rise in non-China tungsten prices, reflecting its pivotal role in critical mineral supply chains. The community is highly bullish, anticipating further upside as the company's major Sangdong mine approaches full production and amidst increasing global demand for secure, non-Chinese tungsten sources essential for defense and technology.

IBEX Ltd. is a business process outsourcing company, which engages in technology-enabled customer lifecycle experience solutions. It also specializes in digital marketing, lead generation, online sales, optimization, lead conversion, customer service, billing support, technical support, multi-lingual, omni-channel, retention, renewals, up and cross sell, and win-backs. The company was founded in 1984 and is headquartered in Washington, DC.

IBEX Ltd

IBEX Ltd. is gaining attention following robust financial results that include record quarterly growth and an upward revision to its fiscal year revenue and adjusted EBITDA guidance. The community is actively discussing its strong fundamentals, strategic focus on AI-powered customer experience, share buybacks, and perceived undervaluation, anticipating further upside.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp is trending due to significant political uncertainty surrounding the extension of Affordable Care Act (ACA) subsidies, with recent proposals facing congressional backlash and creating mixed investor sentiment. The community is actively debating whether current dips are buying opportunities, anticipating an eventual extension, or a reflection of sustained policy headwinds for the healthcare sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Royce & Associates LP Takes Position in Zevra Therapeutics, Inc. $ZVRA

Royce & Associates LP acquired a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the...

Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates

Stevanato (STVN) delivered earnings and revenue surprises of +6.06% and +4.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -9.59% and -33.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of -150.00% and -9.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat...

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevras executive officers and whether investor...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling...

Timothy Sangiovanni Sells 3,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) SVP Timothy Sangiovanni sold 3,000 shares of the company's stock in a transaction dated Tuesday, February 3rd. The shares were sold at an...

Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) CEO Neil Mcfarlane sold 91,000 shares of the firm's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price...

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.05	--	--	N/A
Q3 '25	-$0.03	-$0.01	70.37%	BEAT
Q2 '25	$2.26	$1.21	-46.55%	MISSED
Q1 '25	-$0.18	-$0.06	66.93%	BEAT
Q4 '24	-$0.40	-$0.67	-69.62%	MISSED

ZVRA
Zevra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ZVRA News

ZVRAZevra Therapeutics Inc